Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: Demonstration of schedule-dependent toxicities

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 728-733

  Pazdur, Richard ^a   Lassere, Yvonne ^a   Diaz Canton, Enrique ^a   Bready, Beth ^a   Ho, Dah H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

5 Fluorouracil; Carcinoma; Ftorafur; Rectal carcinoma; Tegafur; Uracil

Indexed keywords

TEGAFUR; UFT; URACIL;

ADULT; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG MIXTURE; FATIGUE; FEMALE; GRANULOCYTOPENIA; HOSPITALIZATION; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 0029966745     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00002     Document Type: Article

References (27)

1. Friedman MA, Ignoffo RH. A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC 148958). Cancer Treat Rev 1980; 7: 205-13.
2. Buroker T, Padilla F, Groppe C. et al. Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group study. Cancer 1979; 44: 48-51.
3. Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ, Clinical evaluation of ftorafur. Cancer Res 1976; 36: 1821-4.
4. Ansfield FJ, Kallas GJ, Singson JP Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol 1983; 1: 107-10.
5. Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil 1-(2-tetrahydrofuryl)-5-fluorouracil. Kagaku Ryobo 1978; 69: 763-72.
6. Fujii S, Okuda H, Toide H, Watanabe N, Taira K, Hashimoto S. Studies on the fate of FT-207, an antitumor agent: absorption, tissue distribution, and excretion. Pharmacokinetics 1974; 8: 589-95.
7. Taguchi T, Nakano Y, Fujita M, et al. Clinical studies of the anticancer activity of FT-207. Jpn J Cancer Clinics 1972; 18: 550-3.
8. Taguchi T, Nakano Y, Jikuya K, Fujii S. Effect of uracil on the antitumor activity of ftorafur. Jpn J Cancer Chemotber 1978; 5: 1161-5.
9. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemotber 1979; 6: 377-84.
10. Ikenaka K, Shirasaka T, Kitano S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Gann 1979; 70: 353-9.
11. Saitoh T Kagaya T, Takebe T, Ishii K. The enhancement of the antitumor effect of FT-207 coadministered with uracil on the transplanted ductal adenocarcinoma of the Syrian goldern hamster pancreas. Jpn J Cancer Chemother 1982; 9: 2168-74.
12. Suemasu K, Nomoto C, Higashi Y. Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT. Jpn J Cancer Chemother 1982, 9: 667-71.
13. Tsujimoto T, Sakai S, Murata M, Sasaki R. Concentrations of 5-FU in the tissue and serum of the patients with head and neck malignant tumors by preoperative administration of UFT. Jpn J Cancer Chemother 1983; 10: 78-83.
14. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT Phase II studies. Cancer Chemother Pharmacol 1988; 22: 333-8.
15. Murakami M, Ota K. Clinical results of UFT therapy for malignant tumors under cooperative study. Jpn J Cancer Chemother 1980; 7: 1579-86.
16. Watanabe H, Yamamoto S, Naito T. Clinical results of oral UFT therapy under cooperative study. Jpn J Cancer Chemother 1980; 7: 1588-96.
17. Ajani JA, Welch SR, Raber MN, et al. Comprehensive criteria for survival in therapy-induced toxicity. Cancer Invest 1990; 8: 141-53.
18. Dorr RT, Von Hoff DD. 5-Fluorouracil. In: Dorr RT. Von Hoff DD, eds. Cancer chemotherapy bandbook. Norwalk, CT: Appleton & Lange 1994: 500-15.
19. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 1995; 13: 1303-11.
20. Hill M, Norman A, Cunningham D. et al. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival. and quality of life in advanced colorectal cancer. J Clin Oncol 1995; 13: 2317-23.
21. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-300.
22. Armstrong RD, Diasio RB. Metabolism and biological activity of 5-deoxy-5 fluorouridine, a novel fluoropyrimidine. Cancer Res 1980; 40: 3333-8.
23. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition of oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-9.
24. Dindogru A, Vaitkevicius VK, Young JD, Horwitz JP, Baker JH. Pharmacologic studies and phase I evaluation of oral ftorafur. Proc Am Ass Cancer Res 1980; 21: 167.
25. Ho DH, Covington WP, Pazdur R, et al. Clinical pharmacology of combined oral uracil and ftorafur. Drug Metab Dispos 1992; 20: 936-40.
26. Malik STA, Talbot D, Clarke PI, Osborne R, Reznek, Wringley PFM, Slevin ML. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990; 62: 1023-5.
27. Saltz LB, Leichman CG, Young CW, et al. A fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. Cancer 1995; 75: 782-5.